Catalyst's Firdapse becomes first FDA-approved drug for rare autoimmune disease

FDA approved a resubmitted NDA for Firdapse amifampridine phosphate from Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX).

Read the full 145 word article

User Sign In